Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as to Quantify Teh Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment.
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2016
At a glance
- Drugs Epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms NADIR
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 31 Dec 2015 Phase of the study changed from III to IV as per ClinicalTrials.gov record.
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.